US20060034857A1 - Notch - Google Patents
Notch Download PDFInfo
- Publication number
- US20060034857A1 US20060034857A1 US11/022,478 US2247804A US2006034857A1 US 20060034857 A1 US20060034857 A1 US 20060034857A1 US 2247804 A US2247804 A US 2247804A US 2006034857 A1 US2006034857 A1 US 2006034857A1
- Authority
- US
- United States
- Prior art keywords
- notch
- cells
- delta
- serrate
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000004027 cell Anatomy 0.000 claims abstract description 84
- 108010070047 Notch Receptors Proteins 0.000 claims abstract description 54
- 239000003446 ligand Substances 0.000 claims abstract description 54
- 102000005650 Notch Receptors Human genes 0.000 claims abstract description 53
- 206010052779 Transplant rejections Diseases 0.000 claims abstract description 8
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 7
- 208000026935 allergic disease Diseases 0.000 claims abstract description 7
- 230000007815 allergy Effects 0.000 claims abstract description 7
- 230000005784 autoimmunity Effects 0.000 claims abstract description 7
- 108010036039 Serrate-Jagged Proteins Proteins 0.000 claims description 47
- 102000011842 Serrate-Jagged Proteins Human genes 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 20
- 230000006044 T cell activation Effects 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 44
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract description 28
- 150000001875 compounds Chemical class 0.000 abstract description 17
- 230000003993 interaction Effects 0.000 abstract description 15
- 238000012986 modification Methods 0.000 abstract description 7
- 230000004048 modification Effects 0.000 abstract description 7
- 208000035473 Communicable disease Diseases 0.000 abstract description 3
- 208000006673 asthma Diseases 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 244000052769 pathogen Species 0.000 abstract description 2
- 239000000427 antigen Substances 0.000 description 45
- 102000036639 antigens Human genes 0.000 description 45
- 108091007433 antigens Proteins 0.000 description 45
- 108090000623 proteins and genes Proteins 0.000 description 41
- 230000014509 gene expression Effects 0.000 description 38
- 108090000765 processed proteins & peptides Proteins 0.000 description 36
- 102000004169 proteins and genes Human genes 0.000 description 28
- 210000004408 hybridoma Anatomy 0.000 description 22
- 239000002953 phosphate buffered saline Substances 0.000 description 17
- 239000013566 allergen Substances 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- 210000004443 dendritic cell Anatomy 0.000 description 15
- 102000000588 Interleukin-2 Human genes 0.000 description 13
- 108010002350 Interleukin-2 Proteins 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 241000700605 Viruses Species 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 210000001165 lymph node Anatomy 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 241001430294 unidentified retrovirus Species 0.000 description 11
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 10
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 230000002458 infectious effect Effects 0.000 description 9
- 108010061629 Dermatophagoides pteronyssinus antigen p 1 Proteins 0.000 description 8
- 108700037638 Neurogenic locus notch homolog protein 1 Proteins 0.000 description 8
- 108700041286 delta Proteins 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000002093 peripheral effect Effects 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000012634 fragment Substances 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 206010062016 Immunosuppression Diseases 0.000 description 5
- 102000049556 Jagged-1 Human genes 0.000 description 5
- 108700003486 Jagged-1 Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000001506 immunosuppresive effect Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 4
- 101000914947 Bungarus multicinctus Long neurotoxin homolog TA-bm16 Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108010058846 Ovalbumin Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 229940092253 ovalbumin Drugs 0.000 description 4
- 230000009696 proliferative response Effects 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 230000000981 bystander Effects 0.000 description 3
- 102000006533 chordin Human genes 0.000 description 3
- 108010008846 chordin Proteins 0.000 description 3
- 239000003184 complementary RNA Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 102000045246 noggin Human genes 0.000 description 3
- 108700007229 noggin Proteins 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 101100510615 Caenorhabditis elegans lag-2 gene Proteins 0.000 description 2
- 101100074828 Caenorhabditis elegans lin-12 gene Proteins 0.000 description 2
- 101100129922 Caenorhabditis elegans pig-1 gene Proteins 0.000 description 2
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- 101100520057 Drosophila melanogaster Pig1 gene Proteins 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 101150021185 FGF gene Proteins 0.000 description 2
- 102000016970 Follistatin Human genes 0.000 description 2
- 108010014612 Follistatin Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 101001124893 Xenopus laevis Nodal homolog 3-A Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 230000008614 cellular interaction Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 210000005220 cytoplasmic tail Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000004073 interleukin-2 production Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 108030001653 Adamalysin Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 101100379376 Caenorhabditis elegans apx-1 gene Proteins 0.000 description 1
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241001533413 Deltavirus Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000244160 Echinococcus Species 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 241001288713 Escherichia coli MC1061 Species 0.000 description 1
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 1
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 102000049546 Jagged-2 Human genes 0.000 description 1
- 108700003489 Jagged-2 Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 description 1
- 102100025246 Neurogenic locus notch homolog protein 2 Human genes 0.000 description 1
- 108700037064 Neurogenic locus notch homolog protein 2 Proteins 0.000 description 1
- 230000005913 Notch signaling pathway Effects 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000003352 cell adhesion assay Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 210000002861 immature t-cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
Definitions
- the present invention relates to use of therapeutic compounds in the modification of T-cell activation.
- it relates to their use in modulating the interaction between Notch protein family members and their ligands and to the use of such compounds in the therapy of conditions such as graft rejection, autoimmunity, allergy, asthma, infectious diseases and tumours.
- T cells and between antigen presenting cells (APC) and T cells are vital to the function of the human immune system.
- APC antigen presenting cells
- T cell or T cell-APC interaction in conditions such as autoimmunity, allergy and graft rejection it is desirable to induce the downregulation of an immune response by stimulation of negative T cell or T cell-APC interaction.
- Models of “infectious tolerance” and “linked suppression” suggest that tolerance may be induced in a small number of T cells and that these T cells then transmit this tolerance to other T cells thus preventing an effective immunological attack.
- immunosuppression is a common feature. In such circumstances it would therefore be desirable to inhibit the T cell interactions passing on the infectious tolerance.
- WO 92/19734 purports to disclose the nucleotide sequences of the human Notch and Delta genes and amino acid sequences of their encoded proteins. The disclosure shows that the Notch gene family has been well characterised as essential to the correct embryological cell lineage development of insects such as Drosophila.
- Proteins belonging to the Notch family are transmembrane receptors that contain several conserved peptide motifs. Each protein within the family displays characteristic extracellular EGF (epidermal growth factor)-like repeats and a juxtamembrane Lin-12/Notch motif. In addition each protein has 6-8 ankyrin repeat motifs on the cytoplasmic tail together with a PEST sequence.
- the Notch ligands have a diagnostic DSL domain (D. Delta, S, Serrate, L, Lag2) comprising 20-22 amino acids at the amino terminus of the protein and between 3-8 EGF-like repeats on the extracellular surface.
- the proteins have a short cytoplasmic tail with no conserved functional domains.
- immunisation with a peptide fragment of antigen under selected conditions may inhibit specific responses not only to itself but to other regions in the same molecule provided the intact protein is used for the challenge immunisation (linked suppression; Hoyne G F, et al. J. Exp Med. 1993; 178:183. and Metzler B, Wraith D C. Int. Immunol. 1993;5:1159).
- the present invention arises from the discovery that the Notch receptor family and its ligands, Delta and Serrate, are expressed on the cell surface of normal adult cells of the peripheral immune system.
- Notch signalling may play a central role in the induction of peripheral unresponsiveness (tolerance or anergy) and may provide a physical explanation for linked suppression and infectious tolerance.
- the present invention further relates to the use of a Notch-ligand in the treatment of a T cell mediated reaction.
- a Notch-ligand expressed by an APC in the presence of an allergen or antigen
- the Notch-ligand is capable of making the T cell population tolerant to said allergen or antigen.
- this T cell population when subsequently exposed to a second population of naive T cells is capable of rendering the second population tolerant to said allergen or antigen.
- the invention also relates to the use of a Notch-ligand in affecting linked tolerance and/or bystander tolerance (also known in the art as infectious tolerance).
- a further embodiment of the invention relates to the use of a Notch-ligand in the modulation of the expression of a functional Notch-protein or Notch signalling pathways.
- the Notch-ligand may be exposed to the T cells by incubating/mixing the T cells with antigen presenting cells (APCs) or the like, that express or overexpress a Notch-ligand in the presence of an allergen or antigen.
- APCs antigen presenting cells
- the (over)expression of the Notch-ligand gene may be brought about by the APCs being transfected with a gene capable of expressing a Notch-ligand or by the APCs being exposed to an agent capable of up-regulating expression of endogenous Notch-ligand gene(s).
- Suitable agents that influence expression of Notch-ligands include agents that affect the expression of Delta and/or Serrate genes.
- BMPs bone morphogenetic proteins, Wilson, P. A. and Hemmati-Brivanlou A. 1997 Neuron 18: 699-710, Hemmati-Brivanlou, A and Melton, D. 1997 Cell 88:13-17
- binding of extracellular BMPs to their receptors leads to down-regulated Delta transcription due to the inhibition of the expression of the Achaete/Scute Complex transcription factor.
- This complex is believed to be directly involved in the regulation of Delta expression.
- any agent that inhibits the binding of BMPs to their receptors is capable of producing an increase in the expression of Delta and/or Serrate.
- Such agents include Noggin, Chordin, Follistatin, Xnr3, FGFs, Fringe and derivatives and variants thereof (see references for noggin-Smith W. C. and Harland, R. M Cell 70:829-840, chordin-Sasai, Yet al., 1994 Cell 79: 779-790).
- Noggin and Chordin bind to BMPs thereby preventing activation of their signalling cascade which leads to decreased Delta transcription.
- the body may be immuno-compromised and it may be desirable to downregulate the expression of Delta and/or Serrate in order to overcome the imposed immunosuppression.
- Agents that inhibit the expression of Delta and/or Serrate may be used in such circumstances.
- agents that inhibit the expression of Delta and/or Serrate include the Toll protein (Medzhitov, R. et al., 1997 Nature 388: 394-397) BMPs and other agents that decrease or interfere with the production of Noggin, Chordin, Follistatin, Xnr3, FGFs and Fringe.
- the invention further relates to the use of an agent capable of downregulating the expression of Delta or Serrate proteins in the manufacture of a medicament for use in reversing bacteria infection or tumour-induced immunosuppression.
- the invention also relates to the modification of Notch-protein expression or presentation on the cell membrane or signalling pathways. These have been shown to be involved in T-cell mediated responses that participate in the induction of tolerance (linked and/or bystander).
- Agents that enhance the presentation of a fully functional Notch-protein on the cell surface include matrix metalloproteinases such as the product of the Kuzbanian gene of Drosophila (Dkuz, Pan, D and Rubin, G. M. 1997 Cell 90: 271-280) and other ADAMALYSIN gene family members.
- Agents that reduce or interfere with its presentation as a fully functional cell membrane protein may include MMP inhibitors such as hydroxymate-based inhibitors.
- APC antigen presenting cell or the like
- suitable APCs include dendritic cells. L cells, hybridomas, lymphomas, macrophages, B cells or synthetic APCs such as lipid membranes.
- the transfection may be brought about by a virus such as a retrovirus or adenovirus, or by any other vehicle or method capable of delivering a gene to the cells.
- viruses such as a retrovirus or adenovirus
- vehicle or method capable of delivering a gene to the cells.
- retroviruses include any vehicles or methods shown to be effective in gene therapy and include retroviruses, liposomes, electroporation, other viruses such as adenovirus, adeno-associated virus, herpes virus, vaccinia, calcium phosphate precipitated DNA, DEAE dextran assisted transfection, microinjection, polyethylene glycol, protein-DNA complexes.
- a virus may be used in combination with liposomes in order to increase the efficiency of DNA uptake.
- the site specificity of the delivery may be achieved by the inclusion of specific proteins (eg a single chain antibody reactive with CD11c for dendritic cells/macrophages) in the viral coat or liposome.
- constructs through which expression of the the gene eg serrate
- APCs (over)expressing Serrate would therefore also express high levels of the relevant antigen and so preferentially interact with T cells of the appropriate specificity.
- a further embodiment of the present invention relates to a molecule comprising a Notch-ligand moiety operably linked to a T cell allergen or antigen moiety such that upon exposure to T cells both moieties are capable of binding to their respective sites.
- a molecule is capable of rendering an antigen/allergen specific T cell tolerant to the allergen or antigen upon which the allergen or antigen moiety is based, as the specificity required of the Notch-ligand moiety is provided by the close proximity of the allergen or antigen moiety.
- the antigen or allergen moiety may be, for example, a synthetic MHC-peptide complex. That is a fragment of the MHC molecule bearing the antigen groove bearing an element of the antigen. Such complexes have been described in Altman J D et al Science 1996 274: 94-6.
- the compound is a fusion protein comprising a segment of Notch or Notch ligand extracellular domain and an immunoglobulin F c segment, preferably IgGF c or IgMF c .
- the Notch-ligand is of the Serrate family of proteins or Delta family of proteins, derivatives, fragments or analogs thereof.
- T cells Diseased or infectious states that may be described as being mediated by T cells include any one or more of asthma, allergy, graft rejection, autoimmunity, tumour induced abberations to the T cell system and infectious diseases such as those caused by Plasmodium species, Microfilariae, Helminths, Mycobacteria, HIV, Cytomegalovirus, Pseudomonas, Toxoplasma, Echinococcus, Haemophilus influenza type B, measles, Hepatitis C or Toxicara.
- a Notch-ligand may be used in accordance with the present invention to treat the said disease or infection.
- the invention also provides a method for detecting immune suppression induced by an invading organism.
- Such organisms may generate soluble forms of family members of Serrate, Notch and/or Delta or derivatives thereof or proteins that affect their expression in vivo, thus inducing infectious tolerance immunosuppression.
- the method comprises an assay for the presence of in vivo non-membrane bound Serrate, Delta, Notch or derivatives thereof and preferably comprises an antibody to Serrate, Delta or Notch or their derivatives.
- Methods of use in screening assays for the detection of increased or decreased Notch, Delta/Serrate expression and/or processing include:
- RT-PCR quantitative-reverse transcriptase-polymerase chain reaction
- Delta/Serrate or Notch expression should lead to increased adhesion between cells expressing Notch and its ligands Delta/Serrate.Test cells will be exposed to a particular treatment in culture and radiolabelled or flourescein labelled target cells (transfected with Notch/Delta/Serrate protein) will be overlayed. Cell mixtures will be incubated at 37 degrees C for 2 hr. Nonadherent cells will be washed away and the level of adherence measured by the level of radioactivity/immunofluorescence at the plate surface.
- the invention also relates to compounds, or Notch-ligands detectable by these assay methods.
- the invention also includes an assay method comprising contacting (a) Notch protein and a ligand capable of binding to the Notch protein with (b) a compound: and determining if the compound affects binding of the ligand to the Notch protein preferably wherein the Notch protein is associated with a T cell.
- the Notch-ligands of use in the present invention are preferably Delta or Serrate family member proteins or polypeptides or derivatives thereof. These are preferably obtained using standard techniques of recombinant technology well known to the person skilled in the art. Appropriate gene sequences for use to generate such compounds of the present invention may be obtained from publications such as WO97/01571, WO 96/27610 and WO 92/19734. The invention is not however in any way limited by the Notch, Delta and Serrate invention is not however in any way limited by the Notch, Delta and Serrate sequences disclosed in these publications.
- Notch ligand further includes any ligand or ligand family member that interacts with a Notch protein family member and includes the group of proteins referred to as “toporythmic proteins” i.e. the protein product of the Delta, Serrate, Deltex and Enhancer of split genes as well as other members of this gene family identifiable by virtue of the ability of their gene sequences to hybridize to, or their homology with Notch, Delta or Serrate proteins, or the ability of their genes to display phenotypic interactions.
- Notch Delta and Serrate were first described in Drosophila and therefore represent prototypic proteins of the Notch receptor and Notch-ligand family members respectively. Multiple Notch proteins and ligands have now been described in many invertebrate and vertebrate species but their nomenclature may differ from that used in the fly. For example Notch is a homolog of Lin 12 and Glp 1, Serrate/Delta are homologs of Jagged, Apx1 and Lag-2.
- compositions of the present invention may be formulated according to principles well known in the art. Thus the nature of the excipient and the amount of activity will depend upon the compound of the present invention which is to be formulated.
- compositions are in unit dosage form.
- Dosages of compounds of the present invention, to be administered to a patient in the form of a pharmaceutical formulation, could be determined by a suitable physician.
- the preferred administration route of a formulation of the present invention is any one of the usual methods of administration including intramuscular and intra-peritoneal, intravenous injection, intranasal inhalation, lung inhalation subcutaneous, intradermal, intra-articular, intrathecal, topical, and via the alimentary tract (for example, via the Peyers patches).
- derivative in relation to proteins or polypeptides of the present invention includes any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acid residues from or to the sequence providing that the resultant protein on polypeptide possesses the capability of modulating Notch-Notch ligand interactions.
- variant in relation to proteins or polypeptides of the present invention includes any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acid residues from or to the sequence providing that the resultant protein on polypeptide possesses the capability of modulating Notch-Notch ligand interactions.
- analog in relation to proteins or polypeptides of the present invention includes any peptidomimetic, that is, a chemical compound that possesses the capability of modulating Notch-Notch ligand interactions in a similar manner to the parent protein or polypeptide. These include compounds that may agonise or antagonise the expression or activity of a Notch-protein or Notch-ligand.
- a compound may be considered to modulate Notch-Notch ligand interactions if it is capable of either inhibiting or enhancing the interaction of Notch with its ligands, preferably to an extent sufficient to provide therapeutic efficacy.
- Notch-Notch ligand means the interaction between a Notch family member and a ligand capable of binding to one or more such member.
- therapy should be taken to encompass diagnostic and prophylactic applications.
- the term “medical” includes human and veterinary applications.
- protein and polypeptide may be assumed to be synonymous, protein merely being used in a general sense to indicate a relatively longer amino acid sequence than that present in a polypeptide.
- FIG. 1 shows the results of in situ hybridisations carried out as described in Example 1 herein;
- FIG. 2 shows the results of the experiment described in Example 4.
- FIG. 3 shows the results of the experiment described in Example 5.
- FIG. 4 shows the results of the experiment described in Example 6.
- FIG. 5 shows the results of the experiment described in Example 7.
- FIG. 6 shows the results of the experiment described in Example 8.
- FIG. 7 shows the results of the experiment described in Example 9.
- FIGS. 8 a and 8 b show the results of the experiment described in Example 10.
- FIG. 9 shows the results of the experiment described in Example 11.
- Antisense RNA probes specific for Notch 1, Delta 1 and Serrate 1 were synthesized and incorporated with digoxigenin labelled-UTP. Each probe was dissolved in hybridisation buffer, heated to 70° C. for 5-10 minutes and added to TESPA coated slides containing 10 mm sections of spleen or thymus that had been previously fixed with 4% paraformaldehyde+PBS. Slides were hybridized overnight at 65° C. The following day, slides were washed twice at 65° C. and twice at room temperature (RT) with 1 ⁇ SSC/50% Formamide/0.1% Tween 20.
- RT room temperature
- Results The results of these hybridisations are shown in FIG. 1 , that shows that in a spleen from a 3 month old mouse, Delta and Serrate are expressed by isolated cells in the periarteriolar sheath and not in the germinal centre (gc). Notch is expressed in many cells again in the periarteriolar sheath.
- the pIG-1 [D. Simmons, “Cloning cell surface molecules by transient surface expression in mammalian cells” pp 93-128, Cellular Interactions in Development Ed. D. Hartley, pub. Ox. Uni. Press (1993)] expression vector allows production of a fusion protein that contains the extracellular portion of Delta 1 linked to the human IgG1-F c domain. A restriction enzyme fragment that contained only the extracellular domain of the Delta 1 protein was cloned into the pIG-1 vector. The resultant plasmid was tranformed into E. Coli MC 1061, and grown in SOB containing 10 ⁇ g/ml tetracycline/ampicillin. Purified vector was used to transfect COS cells in vitro.
- COS cells were grown to 50-75% confluency and transfected with 10 ⁇ g of plasmid DNA per dish by DEAE-dextran method.
- the culture medium was replaced with culture medium containing 1% FCS and cells were cultured for a further 3-6 days in vitro. Cells were spun for 5 mins/5000 rpm to pellet cells and debris, the supernatant was removed and stored until required.
- the Delta-Fc fusion was purified from culture supernatants by adding 2 ml of 50% slurry of protein a Sepharose (Phamacia) and rotated overnight at 4° C. Sepharose beads were isolated by passing culture supernatants through a 0.45 mm filter, washed and transferred to a 10 ml plastic column. The Delta-Fc fusion construct was eluted with 2 ml of elution buffer pH 4.0. The eluate was neutralised by the addition of 1M Tris base.
- TCR T cell receptor
- Peripheral tolerance to self antigens can be analysed in T cell receptor (TCR) transgenic mice in which the TCR ligand is expressed as a self antigen only in the periphery.
- Peripheral tolerance to transplantation antigens can be induced in several ways including recipient pre-treatment with T cell antibodies or blockade of costimulation. It is thereby possible to demonstrate both linked suppression and infectious tolerance.
- Peripheral tolerance to allergens may be induced by the intranasal delivery of allergen derived peptides.
- the expression of Notch-Notch ligands is measured on cells recruited into the airways and/or lymphoid tissues following allergen inhalation and modifications in tolerance demonstrated.
- the expression of Notch-Notch ligands can be measured on the organism (pathogen) and immunocompetent cells in the host.
- LNCs lymph node cells
- T cell hybridomas were transfected with either full length Delta or a control plasmid, such that delta was expressed as a membrane protein. After two days in culture the hybridomas were irradiated to prevent them from proliferating or from producing cytokines. Therefore, the only response which was measured in the assay comes from the lymph node cells alone.
- the irradiated hybridomas were added in increasing numbers to cultures containing the primed LNCs.
- the appropriate antigen i.e. p110-131 or OVA
- Supernatent fluids were then collected and assayed for IL-2 (a major T cell growth factor) content. Proliferative responses of the lymph node cells after 72 hours were also measured.
- FIG. 2 shows the data presented as counts per minute (cpm) 3 H-Tdr incorporation 72 hours after the beginning of culture.
- LNC lymph node cells
- p110-131 LNC are cells primed with Der p1 (p110-131)
- OVA LNC are cells primed with OVA.
- 2BB11 and 2BC3 are two different Der p1 reactive hybridomas.
- DCs Dendritic cells
- the DCs were obtained from the spleen and transfected with either a retrovirus allowing expression of the full length Serrate protein or a control retrovirus.
- the DCs were also pulsed with the HDM peptide p110-131 for 3 hours in vitro at 37° C.
- the DCs were then washed and used to immunise naive mice subcutaneously using 10 5 cells/mouse. After 7 days the draining LNCs were recovered and restimulated in culture with peptide at 4 ⁇ 10 5 cells/well. Since the mice were only immunised with peptide-pulsed DCs this gives us a measure of the ability of these cells to prime an immune response.
- FIG. 3 shows the data presented as cpm of LNCs 72 hours after culture from animals immunised with control transfected (open circles) or serrated transfected (open squares) dendritic cells (DCs).
- mice with DCs expressing Serrate resulted in a 10 fold decrease in the number of cells recovered from lymph nodes when compared to immunisation with control DCs.
- LNCs from mice immunised with DCs+Serrate failed to proliferate (93% reduction on control values, FIG. 3 ) or secrete IL-2 when compared to cells from mice immunised with control DCs.
- T cell hybridomas (reactive with Der p 1) were transfected with a retrovirus containing mouse Delta such that Delta was expressed on the cell surface or with a control retrovirus.
- C57 BL mice were injected with 10 million irradiated hybridomas i.p. and immunised with 50 microgram Der p 1 emulsified in Complete Freunds Adjuvant (CFA) sub-cutaneously. After 7 days the draining lymph node cells were collected and cultured at 4 ⁇ 10 5 cells/well with Der p 1 (10 microgram/ml), peptide 110-131 of Der p 1 (10 microgram/ml), or peptide 81-102 of Der p 1 (10 microgram/ml). Cultures were incubated at 37° C.
- Results of proliferation assays of cells from animals injected with control transfected (puro) or Delta transfected (Delta-FL) are shown in FIG. 4 .
- HA1.7 human T cell clone
- mice Delta mice Delta using a retroviral construct to allow cell surface expression of the Delta protein. Mixing of this cell population with normal HA1.7 prevented subsequent reactivity of these normal HA1.7 with peptide HA306-318 and antigen presenting cells. 5 ⁇ 10 5 HA1.7 were mixed with 1 ⁇ 10 6 irradiated DRB1*0101 pripheral blood mononuclear cells (PBMC)+1 microgram HA306-318 and cultured at 37° C. 6 hours later 5% lymphocult (IL-2 containing medium) was added in a total volume of 1 ml. 24 hours after the initiation of culture Delta or control retrovirus or nothing was added.
- PBMC pripheral blood mononuclear cells
- Clone HA1.7 was mixed with peptide HA306-318 (1.0 microgram/ml) in the presence of L cells expressing HLA-DRB1*0101 (as antigen presenting cells), using 2 ⁇ 10 4 of each cell type.
- the L cells were transfected with either control (puro) or serrate (serrate L cells) expressing retrovirus.
- the proliferative response was measured after 72 hours following addition of tritiated thymidine for the last 8 hours of culture. Results are shown in FIG. 6 for HA1.7 cultures:
- Clone HA1.7 was mixed with peptide HA306-318 and L cells (expressing DRB1*0101 as antigen presenting cells) in the presence of 2% IL-2.
- the L cells were transfected with either control or serrate expressing retrovirus. After 7 days in culture, the HA1.7 were harvested washed and irradiated before being mixed with fresh HA1.7 (using 2 ⁇ 10 4 each population). Cells were cultured for a further 2 days before being stimulated with peptide (1.0 microgram/ml)+normal antigen presenting cells (DRB1*0101 PBMCs). The proliferative response was measured after 72 hours following addition of tritiated thymidine for the last 8 hours of culture. The results are shown in FIG. 7 for fresh HA1.7 cultured:
- HA1.7 induced by serrate expressing L cells prevented the response of normal HA1.7 to a normal antigenic stimulus ( FIG. 7 ). This shows the ability of cells tolerised by exposure to serrate, to pass on their tolerance to a naive cell population (infectious/bystander tolerance).
- mice were injected with 10 7 T cell hybridoma cells transduced with either delta or control retrovirus.
- the hybridoma was 2BC3 which has specificity for peptide 110-131 of Der p1.
- animals received either Der p1 or ovalbumin emulsified in complete Freund's adjuvant. 7 days later, lymph node cells were removed and 4 ⁇ 10 5 cells were cultured in the presence of Der p1 or ovalbumin (using the same antigen that they had already been immunised with).
- the production of IL-2 was measured 24 hours after the start of culture. Stimulation indexes for IL-2 production are shown in FIGS. 8 a (responses of animals immunised with Der p1) and 8 b (responses of animals immunised with OVA) for animals injected with hybridomas transfected with control (puro) or Delta (delta) retrovirus.
- HA1.7 was cultured in the presence of peptide HA306-318 (50 ⁇ g/ml) in the absence of APCs. Such conditions result in a state of tolerance in the HA1.7.
- cells 1.5 ⁇ 10 6
- RNA was prepared from cell pellets by homogenisation in guanidium thiocyanate solution followed by CsCl density centrifugation. 1 ⁇ g RNA was converted into cDNA using an oligo dT primer. Of the resultant cDNA, 1/20th was used in PCR (40 cycles) using primers specific for the human delta homolog.
- C57 BL/6J mice were treated intranasally with either 100 microgram Der p1 peptide 110-131 or a control solution (phosphate buffered saline, PBS) on three consecutive days. Intranasal adminstration of antigen in this way is known to induce tolerance to the antigen. Some animals were then rested for 2 weeks before being rechallenged with antigen by injection of 50 ⁇ g Der p1/CFA subcutaneously into the base of the tail. The superficial lymph nodes and spleens of animals were harvested at various time points thereafter (d0 being the first day of intranasal treatment or antigen rechallenge) and processed for immunohistology or in situ hybridisation.
- PBS phosphate buffered saline
- Data shown in tables 1 and 2 are for immunohistology and in situ hybridisation respectively. Data represent the analysis of tissues from 5 separate mice after intranasal peptide alone (PBS/p 110-131 primary) or intranasal and subcutaneous antigen (PBS/p110-131 rechallenge.
- Basal levels of Notch, Delta and Serrate are expressed in control mice receiving only PBS. Mice dosed intranasally with PBS and subcutaneously with antigen showed a moderate increase in expression of all three molecules within 8 days of rechallenge. Animals given either intranasal peptide alone or intranasal peptide followed by antigen rechallenge showed the same pattern of increased expression of Notch Delta and Serrate which was more rapid and greater than in control mice.
- Notch 1 PBS primary + + + + + PBS rechallenge + + + +/+ +/+ p110-131 primary + + ++ +++ +++ p110-131 rechallenge + + ++ +++ +++ Senate 1 PBS primary + + + + + PBS rechallenge + + +/+ +/+ p110-131 primary + + ++ +++ +++ p110-131 rechallenge + + ++ +++ +++ +++ +++ +++
Abstract
The present invention relates to the use of therapeutic compounds in the modification of T-cell, T-cell antigen presenting cell (APC) interactions and the interactions between pathogenic organisms and immunocompetent cells of a host. In particular it relates to the use of these compounds in the modulation of the interaction between Notch proteins and their ligand and to the use of such compounds in the therapy of conditions such as graft rejection, autoimmunity, allergy, and asthma and infectious diseases.
Description
- The present invention relates to use of therapeutic compounds in the modification of T-cell activation. In particular it relates to their use in modulating the interaction between Notch protein family members and their ligands and to the use of such compounds in the therapy of conditions such as graft rejection, autoimmunity, allergy, asthma, infectious diseases and tumours.
- The controlled interaction between T cells and between antigen presenting cells (APC) and T cells is vital to the function of the human immune system. However in certain pathological states it may be therapeutically beneficial to modify, positively or negatively, such interactions. For example, in conditions such as autoimmunity, allergy and graft rejection it is desirable to induce the downregulation of an immune response by stimulation of negative T cell or T cell-APC interaction. Models of “infectious tolerance” and “linked suppression” suggest that tolerance may be induced in a small number of T cells and that these T cells then transmit this tolerance to other T cells thus preventing an effective immunological attack. In other pathological conditions such as tumour induced immunosuppression, parasitic viral or bacterial infections, immunosuppression is a common feature. In such circumstances it would therefore be desirable to inhibit the T cell interactions passing on the infectious tolerance.
- However until now the mechanisms underlying such T cell and T cell-APC interactions have not been understood.
- WO 92/19734 purports to disclose the nucleotide sequences of the human Notch and Delta genes and amino acid sequences of their encoded proteins. The disclosure shows that the Notch gene family has been well characterised as essential to the correct embryological cell lineage development of insects such as Drosophila.
- Proteins belonging to the Notch family are transmembrane receptors that contain several conserved peptide motifs. Each protein within the family displays characteristic extracellular EGF (epidermal growth factor)-like repeats and a juxtamembrane Lin-12/Notch motif. In addition each protein has 6-8 ankyrin repeat motifs on the cytoplasmic tail together with a PEST sequence. The Notch ligands have a diagnostic DSL domain (D. Delta, S, Serrate, L, Lag2) comprising 20-22 amino acids at the amino terminus of the protein and between 3-8 EGF-like repeats on the extracellular surface. The proteins have a short cytoplasmic tail with no conserved functional domains.
- Recent evidence suggests that Notch signalling contributes to lineage commitment of immature T cells in the thymus, biasing thymocyte development towards the CD8+ lineage which is independent of MHC recognition (Robey E, et al. Cell 1996, 87:483-492). During maturation in the thymus, T cells acquire the ability to distinguish self antigens from those that are non-self, a process termed self tolerance (von Boehmer H, et al. Ann Rev Immunol. 1990;8:531). Mechanisms also exist in the periphery for the induction and maintenance of tolerance and in many respects their importance is under estimated. There are many experimental models of graft rejection, autoimmune disease and specific responses to allergens that clearly illustrate the ability to induce a state of specific unresponsiveness (tolerance or anergy) in the recipient by immunisation with an antigen. From these systems two important findings arise. Firstly, immunisation with a peptide fragment of antigen under selected conditions may inhibit specific responses not only to itself but to other regions in the same molecule provided the intact protein is used for the challenge immunisation (linked suppression; Hoyne G F, et al. J. Exp Med. 1993; 178:183. and Metzler B, Wraith D C. Int. Immunol. 1993;5:1159). Secondly, as best described in experimental models of transplantation is the phenomenon of “infectious tolerance” where it is postulated that immunocompetent cells made tolerant to a specific antigen are able to inhibit other cells from responding and further, that this second population of cells becomes regulatory and tolerant (Qin S X, et al. Science 1993;258:974). The immunological mechanisms underlying these phenomena have not so far been characterised.
- The present invention arises from the discovery that the Notch receptor family and its ligands, Delta and Serrate, are expressed on the cell surface of normal adult cells of the peripheral immune system.
- Hence there is provided according to the present invention, the use of a Notch-ligand in the manufacture of a medicament for use in immunotherapy.
- The expression pattern of the Notch family of receptors and their ligands in the normal peripheral adult immune system has not previously been described but the present inventors have shown that T cells express
Notch 1 mRNA constitutively, while Delta expression is limited to only a subset of T cells in the peripheral lymphoid tissues. Serrate expression appears restricted to a subset of antigen presenting cells (APCs) in the periphery (FIG. 1 ). Hence this receptor ligand family may continue to regulate cell fate decisions in the immune system as has been shown in other tissues, beyond embryonic development (Ellisen L W, et al. Cell 1991;66:649). Notch signalling may play a central role in the induction of peripheral unresponsiveness (tolerance or anergy) and may provide a physical explanation for linked suppression and infectious tolerance. - The present invention further relates to the use of a Notch-ligand in the treatment of a T cell mediated reaction. Thus, it has been observed that by exposing a population of naive T cells to a Notch-ligand expressed by an APC in the presence of an allergen or antigen, the Notch-ligand is capable of making the T cell population tolerant to said allergen or antigen. Furthermore, this T cell population, when subsequently exposed to a second population of naive T cells is capable of rendering the second population tolerant to said allergen or antigen.
- Thus, the invention also relates to the use of a Notch-ligand in affecting linked tolerance and/or bystander tolerance (also known in the art as infectious tolerance).
- A further embodiment of the invention relates to the use of a Notch-ligand in the modulation of the expression of a functional Notch-protein or Notch signalling pathways.
- In the above described embodiments of the present invention, the Notch-ligand may be exposed to the T cells by incubating/mixing the T cells with antigen presenting cells (APCs) or the like, that express or overexpress a Notch-ligand in the presence of an allergen or antigen. The (over)expression of the Notch-ligand gene may be brought about by the APCs being transfected with a gene capable of expressing a Notch-ligand or by the APCs being exposed to an agent capable of up-regulating expression of endogenous Notch-ligand gene(s). Suitable agents that influence expression of Notch-ligands include agents that affect the expression of Delta and/or Serrate genes. For instance, for Delta expression, binding of extracellular BMPs (bone morphogenetic proteins, Wilson, P. A. and Hemmati-Brivanlou A. 1997 Neuron 18: 699-710, Hemmati-Brivanlou, A and Melton, D. 1997 Cell 88:13-17) to their receptors leads to down-regulated Delta transcription due to the inhibition of the expression of the Achaete/Scute Complex transcription factor. This complex is believed to be directly involved in the regulation of Delta expression. Thus, any agent that inhibits the binding of BMPs to their receptors is capable of producing an increase in the expression of Delta and/or Serrate. Such agents include Noggin, Chordin, Follistatin, Xnr3, FGFs, Fringe and derivatives and variants thereof (see references for noggin-Smith W. C. and Harland, R. M Cell 70:829-840, chordin-Sasai, Yet al., 1994 Cell 79: 779-790). Noggin and Chordin bind to BMPs thereby preventing activation of their signalling cascade which leads to decreased Delta transcription.
- In some disease states, the body may be immuno-compromised and it may be desirable to downregulate the expression of Delta and/or Serrate in order to overcome the imposed immunosuppression. Agents that inhibit the expression of Delta and/or Serrate may be used in such circumstances. An example of agents that inhibit the expression of Delta and/or Serrate include the Toll protein (Medzhitov, R. et al., 1997 Nature 388: 394-397) BMPs and other agents that decrease or interfere with the production of Noggin, Chordin, Follistatin, Xnr3, FGFs and Fringe. Thus, the invention further relates to the use of an agent capable of downregulating the expression of Delta or Serrate proteins in the manufacture of a medicament for use in reversing bacteria infection or tumour-induced immunosuppression.
- As discussed above, the invention also relates to the modification of Notch-protein expression or presentation on the cell membrane or signalling pathways. These have been shown to be involved in T-cell mediated responses that participate in the induction of tolerance (linked and/or bystander). Agents that enhance the presentation of a fully functional Notch-protein on the cell surface include matrix metalloproteinases such as the product of the Kuzbanian gene of Drosophila (Dkuz, Pan, D and Rubin, G. M. 1997 Cell 90: 271-280) and other ADAMALYSIN gene family members. Agents that reduce or interfere with its presentation as a fully functional cell membrane protein may include MMP inhibitors such as hydroxymate-based inhibitors.
- The term “antigen presenting cell or the like” as used herein, is not intended to be limited to APCs. The skilled man will understand that any vehicle capable of presenting the desired Notch-ligand to the T cell population may be used for the sake of convenience the term APCs is used to refer to all these. Thus examples of suitable APCs include dendritic cells. L cells, hybridomas, lymphomas, macrophages, B cells or synthetic APCs such as lipid membranes.
- When the APCs are transfected with a gene capable of expressing a Notch-ligand, the transfection may be brought about by a virus such as a retrovirus or adenovirus, or by any other vehicle or method capable of delivering a gene to the cells. These include any vehicles or methods shown to be effective in gene therapy and include retroviruses, liposomes, electroporation, other viruses such as adenovirus, adeno-associated virus, herpes virus, vaccinia, calcium phosphate precipitated DNA, DEAE dextran assisted transfection, microinjection, polyethylene glycol, protein-DNA complexes.
- Using such vehicles or methods alone or in combination it is possible to site-direct the gene delivery to a particular population of cells, thus enabling the method of the present invention to be performed in vivo. For example, a virus may be used in combination with liposomes in order to increase the efficiency of DNA uptake. The site specificity of the delivery may be achieved by the inclusion of specific proteins (eg a single chain antibody reactive with CD11c for dendritic cells/macrophages) in the viral coat or liposome.
- Preferably, constructs through which expression of the the gene (eg serrate) is linked to antigen expression would be used. APCs (over)expressing Serrate would therefore also express high levels of the relevant antigen and so preferentially interact with T cells of the appropriate specificity.
- A further embodiment of the present invention relates to a molecule comprising a Notch-ligand moiety operably linked to a T cell allergen or antigen moiety such that upon exposure to T cells both moieties are capable of binding to their respective sites. Such a molecule is capable of rendering an antigen/allergen specific T cell tolerant to the allergen or antigen upon which the allergen or antigen moiety is based, as the specificity required of the Notch-ligand moiety is provided by the close proximity of the allergen or antigen moiety.
- The antigen or allergen moiety may be, for example, a synthetic MHC-peptide complex. That is a fragment of the MHC molecule bearing the antigen groove bearing an element of the antigen. Such complexes have been described in Altman J D et al Science 1996 274: 94-6.
- In a further preferred embodiment, the compound is a fusion protein comprising a segment of Notch or Notch ligand extracellular domain and an immunoglobulin Fc segment, preferably IgGFc or IgMFc.
- In all the above described embodiments of the present invention, it is preferable that the Notch-ligand is of the Serrate family of proteins or Delta family of proteins, derivatives, fragments or analogs thereof.
- Diseased or infectious states that may be described as being mediated by T cells include any one or more of asthma, allergy, graft rejection, autoimmunity, tumour induced abberations to the T cell system and infectious diseases such as those caused by Plasmodium species, Microfilariae, Helminths, Mycobacteria, HIV, Cytomegalovirus, Pseudomonas, Toxoplasma, Echinococcus, Haemophilus influenza type B, measles, Hepatitis C or Toxicara. Thus, with use of the appropriate allergen or antigen, a Notch-ligand may be used in accordance with the present invention to treat the said disease or infection.
- The invention also provides a method for detecting immune suppression induced by an invading organism. Such organisms may generate soluble forms of family members of Serrate, Notch and/or Delta or derivatives thereof or proteins that affect their expression in vivo, thus inducing infectious tolerance immunosuppression. The method comprises an assay for the presence of in vivo non-membrane bound Serrate, Delta, Notch or derivatives thereof and preferably comprises an antibody to Serrate, Delta or Notch or their derivatives.
- Methods of use in screening assays for the detection of increased or decreased Notch, Delta/Serrate expression and/or processing include:
- 1. Delta/Serrate, Notch and Fringe expression being assessed following exposure of isolated cells to test compounds in culture using for example:
- (a) at the protein level by specific antibody staining using immunohistochemistry or flow cytometry.
- (b) at the RNA level by quantitative-reverse transcriptase-polymerase chain reaction (RT-PCR). RT-PCR may be performed using a control plasmid with in-built standards for measuring endogenous gene expression with primers specific for
Notch 1 andNotch 2,Serrate 1 andSerrate 2,Delta 1 andDelta 2,Delta 3 and Fringe. This construct may be modified as new ligand members are identified. - (c) at the functional level in cell adhesion assays.
- Increased Delta/Serrate or Notch expression should lead to increased adhesion between cells expressing Notch and its ligands Delta/Serrate.Test cells will be exposed to a particular treatment in culture and radiolabelled or flourescein labelled target cells (transfected with Notch/Delta/Serrate protein) will be overlayed. Cell mixtures will be incubated at 37 degrees C for 2 hr. Nonadherent cells will be washed away and the level of adherence measured by the level of radioactivity/immunofluorescence at the plate surface.
- Using such methods it is possible to detect compounds or Notch-ligands that affect the expression or processing of a Notch-protein or Notch-ligand. The invention also relates to compounds, or Notch-ligands detectable by these assay methods.
- The invention also includes an assay method comprising contacting (a) Notch protein and a ligand capable of binding to the Notch protein with (b) a compound: and determining if the compound affects binding of the ligand to the Notch protein preferably wherein the Notch protein is associated with a T cell.
- The Notch-ligands of use in the present invention are preferably Delta or Serrate family member proteins or polypeptides or derivatives thereof. These are preferably obtained using standard techniques of recombinant technology well known to the person skilled in the art. Appropriate gene sequences for use to generate such compounds of the present invention may be obtained from publications such as WO97/01571, WO 96/27610 and WO 92/19734. The invention is not however in any way limited by the Notch, Delta and Serrate invention is not however in any way limited by the Notch, Delta and Serrate sequences disclosed in these publications. More preferably, such Notch, Delta or Serrate or family members, proteins or polypeptides or derivatives therefrom are fragments of the extracellular domains of Notch, Delta or Serrate, or family members or are derivatives of such fragments. As used herein, the term “Notch ligand” further includes any ligand or ligand family member that interacts with a Notch protein family member and includes the group of proteins referred to as “toporythmic proteins” i.e. the protein product of the Delta, Serrate, Deltex and Enhancer of split genes as well as other members of this gene family identifiable by virtue of the ability of their gene sequences to hybridize to, or their homology with Notch, Delta or Serrate proteins, or the ability of their genes to display phenotypic interactions.
- Notch, Delta and Serrate were first described in Drosophila and therefore represent prototypic proteins of the Notch receptor and Notch-ligand family members respectively. Multiple Notch proteins and ligands have now been described in many invertebrate and vertebrate species but their nomenclature may differ from that used in the fly. For example Notch is a homolog of Lin 12 and
Glp 1, Serrate/Delta are homologs of Jagged, Apx1 and Lag-2. - Pharmaceutical formulations of the present invention may be formulated according to principles well known in the art. Thus the nature of the excipient and the amount of activity will depend upon the compound of the present invention which is to be formulated.
- Preferably the pharmaceutical compositions are in unit dosage form.
- Dosages of compounds of the present invention, to be administered to a patient in the form of a pharmaceutical formulation, could be determined by a suitable physician.
- The preferred administration route of a formulation of the present invention is any one of the usual methods of administration including intramuscular and intra-peritoneal, intravenous injection, intranasal inhalation, lung inhalation subcutaneous, intradermal, intra-articular, intrathecal, topical, and via the alimentary tract (for example, via the Peyers patches).
- The term “derivative” as used herein, in relation to proteins or polypeptides of the present invention includes any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acid residues from or to the sequence providing that the resultant protein on polypeptide possesses the capability of modulating Notch-Notch ligand interactions.
- The term “variant” as used herein, in relation to proteins or polypeptides of the present invention includes any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acid residues from or to the sequence providing that the resultant protein on polypeptide possesses the capability of modulating Notch-Notch ligand interactions.
- The term “analog” as used herein, in relation to proteins or polypeptides of the present invention includes any peptidomimetic, that is, a chemical compound that possesses the capability of modulating Notch-Notch ligand interactions in a similar manner to the parent protein or polypeptide. These include compounds that may agonise or antagonise the expression or activity of a Notch-protein or Notch-ligand.
- A compound may be considered to modulate Notch-Notch ligand interactions if it is capable of either inhibiting or enhancing the interaction of Notch with its ligands, preferably to an extent sufficient to provide therapeutic efficacy.
- The expression “Notch-Notch ligand” as used herein means the interaction between a Notch family member and a ligand capable of binding to one or more such member.
- The term therapy as used herein should be taken to encompass diagnostic and prophylactic applications.
- The term “medical” includes human and veterinary applications.
- As used herein, the terms protein and polypeptide may be assumed to be synonymous, protein merely being used in a general sense to indicate a relatively longer amino acid sequence than that present in a polypeptide.
- The present invention will now be described by way of non-limiting example, with reference to the accompanying drawings, in which:
-
FIG. 1 shows the results of in situ hybridisations carried out as described in Example 1 herein; -
FIG. 2 shows the results of the experiment described in Example 4. -
FIG. 3 shows the results of the experiment described in Example 5. -
FIG. 4 shows the results of the experiment described in Example 6. -
FIG. 5 shows the results of the experiment described in Example 7. -
FIG. 6 shows the results of the experiment described in Example 8. -
FIG. 7 shows the results of the experiment described in Example 9. -
FIGS. 8 a and 8 b show the results of the experiment described in Example 10. -
FIG. 9 shows the results of the experiment described in Example 11. - Antisense RNA probes specific for
Notch 1,Delta 1 andSerrate 1 were synthesized and incorporated with digoxigenin labelled-UTP. Each probe was dissolved in hybridisation buffer, heated to 70° C. for 5-10 minutes and added to TESPA coated slides containing 10 mm sections of spleen or thymus that had been previously fixed with 4% paraformaldehyde+PBS. Slides were hybridized overnight at 65° C. The following day, slides were washed twice at 65° C. and twice at room temperature (RT) with 1×SSC/50% Formamide/0.1% Tween 20. Slides were washed twice with 0.1M maleic acid/0.15M NaCl/0.1% tween 20 pH 7.5 (MABT) buffer at RT and then blocked for 2 h with MABT+20% goat serum+296 Boehringer blocking reagent (BBR). Slides were incubated overnight at RT with anti-digoxidenin Fab fragments. After four washes with MABT slides were washed a further two times in alkaline substrate buffer. The presence of bound anti-sense RNA probes was detected by incubating slides in substrate buffer containing NBT+BCIP in the dark. Slides were conterstained with haemotoxylin and mounted in Depx mounting medium. - Results: The results of these hybridisations are shown in
FIG. 1 , that shows that in a spleen from a 3 month old mouse, Delta and Serrate are expressed by isolated cells in the periarteriolar sheath and not in the germinal centre (gc). Notch is expressed in many cells again in the periarteriolar sheath. - The pIG-1 [D. Simmons, “Cloning cell surface molecules by transient surface expression in mammalian cells” pp 93-128, Cellular Interactions in Development Ed. D. Hartley, pub. Ox. Uni. Press (1993)] expression vector allows production of a fusion protein that contains the extracellular portion of
Delta 1 linked to the human IgG1-Fc domain. A restriction enzyme fragment that contained only the extracellular domain of theDelta 1 protein was cloned into the pIG-1 vector. The resultant plasmid was tranformed into E. Coli MC 1061, and grown in SOB containing 10 μg/ml tetracycline/ampicillin. Purified vector was used to transfect COS cells in vitro. COS cells were grown to 50-75% confluency and transfected with 10 μg of plasmid DNA per dish by DEAE-dextran method. At 24 h post transfection the culture medium was replaced with culture medium containing 1% FCS and cells were cultured for a further 3-6 days in vitro. Cells were spun for 5 mins/5000 rpm to pellet cells and debris, the supernatant was removed and stored until required. The Delta-Fc fusion was purified from culture supernatants by adding 2 ml of 50% slurry of protein a Sepharose (Phamacia) and rotated overnight at 4° C. Sepharose beads were isolated by passing culture supernatants through a 0.45 mm filter, washed and transferred to a 10 ml plastic column. The Delta-Fc fusion construct was eluted with 2 ml of elution buffer pH 4.0. The eluate was neutralised by the addition of 1M Tris base. - Peripheral tolerance to self antigens can be analysed in T cell receptor (TCR) transgenic mice in which the TCR ligand is expressed as a self antigen only in the periphery. Peripheral tolerance to transplantation antigens can be induced in several ways including recipient pre-treatment with T cell antibodies or blockade of costimulation. It is thereby possible to demonstrate both linked suppression and infectious tolerance. Peripheral tolerance to allergens may be induced by the intranasal delivery of allergen derived peptides. The expression of Notch-Notch ligands is measured on cells recruited into the airways and/or lymphoid tissues following allergen inhalation and modifications in tolerance demonstrated. Furthermore, in experimental models of infections with infectious agents, the expression of Notch-Notch ligands can be measured on the organism (pathogen) and immunocompetent cells in the host.
- Mice were immunised with a synthetic peptide containing an immunodominant epitope of the house dust mite allergen (HDM), Der p1 (p110-31), or with ovalbumin (OVA, hen egg white protein). One week later the lymph node cells (LNCs) were removed and cell suspensions made. Lymph nodes from animals immunised with different antigens were kept separate. These cells are referred to as primed LNCs.
- T cell hybridomas were transfected with either full length Delta or a control plasmid, such that delta was expressed as a membrane protein. After two days in culture the hybridomas were irradiated to prevent them from proliferating or from producing cytokines. Therefore, the only response which was measured in the assay comes from the lymph node cells alone.
- The irradiated hybridomas were added in increasing numbers to cultures containing the primed LNCs. The appropriate antigen (i.e. p110-131 or OVA) was added and the cells cultured for 24 hours. Supernatent fluids were then collected and assayed for IL-2 (a major T cell growth factor) content. Proliferative responses of the lymph node cells after 72 hours were also measured.
- Results: Lymph node cells cultured in the presence of irradiated hybridomas that expressed a control plasmid still proliferated as shown in
FIG. 2 and secreted IL-2 when stimulated in culture with the appropriate antigen. Their responsiveness was maintained at a ratio of 1:1 LNC:hybridoma. In contrast, the proliferative response and production of IL-2 by lymph node cells was reduced by at least 88% when cultured in the presence of hybridomas expressing full length Delta (at a ratio of 1:1) with the appropriate antigen. Hybridomas transfected with control virus (open circles), delta virus (open squares).FIG. 2 shows the data presented as counts per minute (cpm) 3H-Tdr incorporation 72 hours after the beginning of culture. Cpm of lymph node cells (LNC) cultured with hybridomas expressing delta or control constructs. Total numbers of cells/well=4×105 (i.e the number of LNCs varies according to the ratio of hybridomas to LNC, so the cpm will vary). p110-131 LNC are cells primed with Der p1 (p110-131), OVA LNC are cells primed with OVA. 2BB11 and 2BC3 are two different Der p1 reactive hybridomas. - These data show that inhibition of responses by Delta expressing T cells can be delivered in trans. Although in this culture system Delta expressing T hybridomas specific for
Derp 1 were able to inhibit the response of OVA primed T cells, this apparent lack of specificity appears to be due to the close proximity of cells forced by the culture system. Indeed, the data shown inFIGS. 8 a and 8 b show that in animals the delta expressing hybridoma must share antigen specificity with the immunogen for there to be an modulating effect on the immune response to that immunogen. In this case it appears that the delta expressing T cells can only be brought into proximity with the responding T cells if they recognise the same antigen on the same APC. - Dendritic cells (DCs) are the primary antigen presenting cell in the immune system and are critical for stimulating T cell responses. DCs were obtained from the spleen and transfected with either a retrovirus allowing expression of the full length Serrate protein or a control retrovirus. The DCs were also pulsed with the HDM peptide p110-131 for 3 hours in vitro at 37° C. The DCs were then washed and used to immunise naive mice subcutaneously using 105 cells/mouse. After 7 days the draining LNCs were recovered and restimulated in culture with peptide at 4×105 cells/well. Since the mice were only immunised with peptide-pulsed DCs this gives us a measure of the ability of these cells to prime an immune response.
- Results:
FIG. 3 shows the data presented as cpm of LNCs 72 hours after culture from animals immunised with control transfected (open circles) or serrated transfected (open squares) dendritic cells (DCs). - Immunisation of mice with DCs expressing Serrate resulted in a 10 fold decrease in the number of cells recovered from lymph nodes when compared to immunisation with control DCs. We further found that LNCs from mice immunised with DCs+Serrate failed to proliferate (93% reduction on control values,
FIG. 3 ) or secrete IL-2 when compared to cells from mice immunised with control DCs. - T cell hybridomas (reactive with Der p 1) were transfected with a retrovirus containing mouse Delta such that Delta was expressed on the cell surface or with a control retrovirus. C57 BL mice were injected with 10 million irradiated hybridomas i.p. and immunised with 50
microgram Der p 1 emulsified in Complete Freunds Adjuvant (CFA) sub-cutaneously. After 7 days the draining lymph node cells were collected and cultured at 4×105 cells/well with Der p 1 (10 microgram/ml), peptide 110-131 of Der p 1 (10 microgram/ml), or peptide 81-102 of Der p 1 (10 microgram/ml). Cultures were incubated at 37° C. for 72 hours and tritiated thymidine added for the final 8 hours of culture. Results of proliferation assays of cells from animals injected with control transfected (puro) or Delta transfected (Delta-FL) are shown inFIG. 4 . - Results: LNC from animals injected with control virus transfected hybridomas produced high levels of IL-2 and proliferated in culture in the presence of
Der p 1, peptide 110-131 or peptide 81-102. In contrast, cells from animals injected with Delta expressing hybridomas made no response to any of theDer p 1 antigens (FIG. 4 ). - An influenza-reactive human T cell clone (HA1.7) was transfected with mouse Delta using a retroviral construct to allow cell surface expression of the Delta protein. Mixing of this cell population with normal HA1.7 prevented subsequent reactivity of these normal HA1.7 with peptide HA306-318 and antigen presenting cells. 5×105 HA1.7 were mixed with 1×106 irradiated DRB1*0101 pripheral blood mononuclear cells (PBMC)+1 microgram HA306-318 and cultured at 37° C. 6 hours later 5% lymphocult (IL-2 containing medium) was added in a total volume of 1 ml. 24 hours after the initiation of culture Delta or control retrovirus or nothing was added. 7 days after the start of culture, cells were harvested, washed and the transfected cells irradiated. The transfected cells were mixed at a ratio of 2:1 with untreated HA1.7 and cultured for 2 days. Mixed cultures were then harvested, washed and plated out using 2×104 viable cells/well together with
- a) 2.5×104 DRB1*0101 PBMCs (medium)
- b) 2.5×104 DRB1*0101 PBMCs+peptide (Ag+APC)
- c) 5% lymphocult (IL-2)
- Cells were harvested after 68 hours with the addition of tritiated thymidine for the final 8 hours. The results are shown in
FIG. 5 . - Results: Following culture alone or with control virus transfected HA1.7, untreated HA1.7 responds well to peptide+antigen presenting cells. Incubation with Delta transfected irradiated HA1.7 completely prevents the response of untreated HA1.7 to antigen+APC. However, such cells respond as well as untreated or control virus incubated HA1.7 to IL-2, indicating that they are not simply unable to proliferate (
FIG. 5 ). - Clone HA1.7 was mixed with peptide HA306-318 (1.0 microgram/ml) in the presence of L cells expressing HLA-DRB1*0101 (as antigen presenting cells), using 2×104 of each cell type. The L cells were transfected with either control (puro) or serrate (serrate L cells) expressing retrovirus. The proliferative response was measured after 72 hours following addition of tritiated thymidine for the last 8 hours of culture. Results are shown in
FIG. 6 for HA1.7 cultures: -
-
-
-
-
- Results: HA1.7 stimulated by serrate expressing L cells responded poorly to antigen when compared with those stimulated by control transfected L cells (
FIG. 6 ). - Clone HA1.7 was mixed with peptide HA306-318 and L cells (expressing DRB1*0101 as antigen presenting cells) in the presence of 2% IL-2. The L cells were transfected with either control or serrate expressing retrovirus. After 7 days in culture, the HA1.7 were harvested washed and irradiated before being mixed with fresh HA1.7 (using 2×104 each population). Cells were cultured for a further 2 days before being stimulated with peptide (1.0 microgram/ml)+normal antigen presenting cells (DRB1*0101 PBMCs). The proliferative response was measured after 72 hours following addition of tritiated thymidine for the last 8 hours of culture. The results are shown in
FIG. 7 for fresh HA1.7 cultured: -
-
-
-
- Results: HA1.7 induced by serrate expressing L cells (Serrate induced HA1.7) prevented the response of normal HA1.7 to a normal antigenic stimulus (
FIG. 7 ). This shows the ability of cells tolerised by exposure to serrate, to pass on their tolerance to a naive cell population (infectious/bystander tolerance). - Mice were injected with 107 T cell hybridoma cells transduced with either delta or control retrovirus. The hybridoma was 2BC3 which has specificity for peptide 110-131 of Der p1. At the same time, animals received either Der p1 or ovalbumin emulsified in complete Freund's adjuvant. 7 days later, lymph node cells were removed and 4×105 cells were cultured in the presence of Der p1 or ovalbumin (using the same antigen that they had already been immunised with). The production of IL-2 was measured 24 hours after the start of culture. Stimulation indexes for IL-2 production are shown in
FIGS. 8 a (responses of animals immunised with Der p1) and 8 b (responses of animals immunised with OVA) for animals injected with hybridomas transfected with control (puro) or Delta (delta) retrovirus. - Results: The response to Der p1 in animals injected with delta expressing 2BC3 hybridomas was virtually completely abolished whereas the response to ovalbumin was unaffected. These data are shown in
FIGS. 8 a and 8 b where each dot represents the IL-2 production by an individual mouse to antigen as a stimulation index (SI) of control responses (no antigen added). - HA1.7 was cultured in the presence of peptide HA306-318 (50 μg/ml) in the absence of APCs. Such conditions result in a state of tolerance in the HA1.7. After 0, 30, 120, 240 or 360 minutes, cells (1.5×106) were harvested, pelleted and frozen. RNA was prepared from cell pellets by homogenisation in guanidium thiocyanate solution followed by CsCl density centrifugation. 1 μg RNA was converted into cDNA using an oligo dT primer. Of the resultant cDNA, 1/20th was used in PCR (40 cycles) using primers specific for the human delta homolog. PCR samples were analysed by gel electrophoresis (
FIG. 9 ) whereinlane 1, marker,lane 2, t=0,lane 3, t30 min,lane 4, t=120 min,lane 5, t=240 min,lane 6, t=360 min andlane 7 is the negative control. - Results: Resting HA1.7 did not express Delta mRNA, but transcripts appeared within 2 hours of initiation of the tolerisation protocol.
- C57 BL/6J mice were treated intranasally with either 100 microgram Der p1 peptide 110-131 or a control solution (phosphate buffered saline, PBS) on three consecutive days. Intranasal adminstration of antigen in this way is known to induce tolerance to the antigen. Some animals were then rested for 2 weeks before being rechallenged with antigen by injection of 50 μg Der p1/CFA subcutaneously into the base of the tail. The superficial lymph nodes and spleens of animals were harvested at various time points thereafter (d0 being the first day of intranasal treatment or antigen rechallenge) and processed for immunohistology or in situ hybridisation. For immunohistology, tissues were frozen and 3 μm sections cut, fixed in ice cold acetone and stained with polyclonal antibodies specific for
Notch 1 andSerrate 1. Bound antibody was detected using a horseradish peroxidase conjugated goat anti-rabbit antibody developed with diaminobenzidine as the substrate.Delta 1 specific antibodies were not available for the study. For in situ hybridisation, frozen tissues were sectioned and fixed in 4% paraformaldehyde. Sections were hybridised with digoxigenin coupled antisense RNA probes specific forNotch 1,Serrate 1 andDelta 1 at 65° C. Bound probe was detected by alkaline phosphatase conjugated goat anti-digoxigenin antibody developed using NBT and BCIP as the substrate. Data shown in tables 1 and 2 are for immunohistology and in situ hybridisation respectively. Data represent the analysis of tissues from 5 separate mice after intranasal peptide alone (PBS/p 110-131 primary) or intranasal and subcutaneous antigen (PBS/p110-131 rechallenge. - + weak staining, ++ moderate staining, +++ stong staining.
- Results:
- Basal levels of Notch, Delta and Serrate are expressed in control mice receiving only PBS. Mice dosed intranasally with PBS and subcutaneously with antigen showed a moderate increase in expression of all three molecules within 8 days of rechallenge. Animals given either intranasal peptide alone or intranasal peptide followed by antigen rechallenge showed the same pattern of increased expression of Notch Delta and Serrate which was more rapid and greater than in control mice.
TABLE 1 Expression of Notch and Serrate proteins during the induction of tolerance treatment day 0 day 1day 4day 8day 12 Notch 1PBS primary + + + + + PBS rechallenge + + + +/+ +/+ p110-131 primary + + ++ +++ +++ p110-131 rechallenge + + ++ +++ +++ Senate 1PBS primary + + + + + PBS rechallenge + + + +/+ +/+ p110-131 primary + + ++ +++ +++ p110-131 rechallenge + + ++ +++ +++ -
TABLE 2 Expression of Notch,Delta and Serrate transcripts during the induction of tolerance treatment day 0 day 1day 4day 8day 12 Notch 1PBS primary + + + + + PBS rechallenge + + + +/+ +/+ p110-131 primary + + ++ +++ +++ p110-131 rechallenge + + ++ +++ +++ Senate 1PBS primary + + + + + PBS rechallenge + + + +/+ +/+ p110-131 primary + + ++ +++ +++ p110-131 rechallenge + + ++ +++ +++ Delta 1PBS primary + + + + + PBS rechallenge + + + +/+ +/+ p110-131 primary + + ++ +++ +++ p110-131 rechallenge + + ++ +++ +++ - Other modifications of the present invention will be apparent to those skilled in the present art.
Claims (9)
1-26. (canceled)
27. A method of reducing T-cell activation comprising administering a composition comprising an isolated polynucleotide encoding a Notch ligand comprising a DSL domain to a cell of a patient in need thereof, wherein the Notch ligand is expressed and interacts with a Notch receptor, thereby reducing T-cell activation.
28. The method of claim 27 wherein the Notch ligand comprises Serrate.
29. The method of claim 27 wherein the Notch ligand comprises Delta.
30. The method of any one of claims 27-29, wherein the T-cell activation occurs with allergy, graft rejection, autoimmunity or any of allergy, graft rejection and autoimmunity in combination.
31. The method of claim of claim 30 , wherein the T-cell activation occurs with allergy.
32. The method of claim 30 , wherein the T-cell activation occurs with graft rejection.
33. The method of claims 30, wherein the T-cell activation occurs with autoimmunity.
34. The method of claim 30 , wherein the method comprises administering the composition to the patient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/022,478 US20060034857A1 (en) | 1996-11-07 | 2004-12-22 | Notch |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9623236.8A GB9623236D0 (en) | 1996-11-07 | 1996-11-07 | Notch |
GB9623236.8 | 1996-11-07 | ||
GBGB9715674.9A GB9715674D0 (en) | 1997-07-24 | 1997-07-24 | Notch |
GB9715674.9 | 1997-07-24 | ||
GBGB9719350.2A GB9719350D0 (en) | 1997-09-11 | 1997-09-11 | Notch |
GB9719350.2 | 1997-09-11 | ||
PCT/GB1997/003058 WO1998020142A1 (en) | 1996-11-07 | 1997-11-06 | Notch |
US09/310,685 US6887475B1 (en) | 1996-11-07 | 1999-05-04 | Notch |
US11/022,478 US20060034857A1 (en) | 1996-11-07 | 2004-12-22 | Notch |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/310,685 Continuation US6887475B1 (en) | 1996-11-07 | 1999-05-04 | Notch |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060034857A1 true US20060034857A1 (en) | 2006-02-16 |
Family
ID=33458905
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/310,685 Expired - Fee Related US6887475B1 (en) | 1996-11-07 | 1999-05-04 | Notch |
US10/877,563 Expired - Fee Related US7399741B2 (en) | 1996-11-07 | 2004-06-25 | Notch |
US11/022,478 Abandoned US20060034857A1 (en) | 1996-11-07 | 2004-12-22 | Notch |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/310,685 Expired - Fee Related US6887475B1 (en) | 1996-11-07 | 1999-05-04 | Notch |
US10/877,563 Expired - Fee Related US7399741B2 (en) | 1996-11-07 | 2004-06-25 | Notch |
Country Status (1)
Country | Link |
---|---|
US (3) | US6887475B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080317760A1 (en) * | 2007-05-15 | 2008-12-25 | Austin Gurney | Compositions and Methods for Diagnosing and Treating Cancer |
US8945569B2 (en) | 2009-11-19 | 2015-02-03 | Oncomed Pharmaceuticals, Inc. | Jagged-binding agents and uses thereof |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6887475B1 (en) * | 1996-11-07 | 2005-05-03 | Lorantis Limited | Notch |
GB9927328D0 (en) * | 1999-11-18 | 2000-01-12 | Lorantis Ltd | Immunotherapy |
GB0123379D0 (en) * | 2001-09-28 | 2001-11-21 | Lorantis Ltd | Modulators |
GB0201674D0 (en) * | 2002-01-25 | 2002-03-13 | Lorantis Ltd | Medical treatment |
US20060084599A1 (en) * | 2003-03-05 | 2006-04-20 | Maine Medical Center | Compositions, methods and kits relating to notch signaling |
ATE474593T1 (en) * | 2003-03-21 | 2010-08-15 | Celldex Therapeutics Ltd | TREATMENT OF ALLERGIC DISEASES USING A MODULATOR OF THE NOTCH SIGNALING PATHWAY |
WO2010091679A2 (en) * | 2009-02-16 | 2010-08-19 | Deutsches Rheuma-Forschungszentrum Berlin | Use of notch regulators for modulating the immune response by induction/suppression of interleukin-22 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6004924A (en) * | 1991-12-11 | 1999-12-21 | Imperial Cancer Research Technology, Ltd. | Protein sequences of serrate gene products |
US20010048930A1 (en) * | 1999-12-15 | 2001-12-06 | Lamb Jonathan Robert | Methods of immunosuppression |
US7399741B2 (en) * | 1996-11-07 | 2008-07-15 | Celldex Therapeutics Limited | Notch |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL101728A (en) | 1991-05-03 | 2007-08-19 | Univ Yale | Human notch and delta, binding domains in toporythmic proteins, and methods based thereon |
US5869282A (en) | 1991-12-11 | 1999-02-09 | Imperial Cancer Research Technology, Ltd. | Nucleotide and protein sequences of the serrate gene and methods based thereon |
US5786158A (en) | 1992-04-30 | 1998-07-28 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
US5750652A (en) | 1994-01-21 | 1998-05-12 | Yale University | Deltex proteins |
AU689214B2 (en) | 1994-02-01 | 1998-03-26 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Fusion proteins that include antibody and nonantibody portions |
ES2334953T3 (en) | 1995-06-28 | 2010-03-17 | Imperial Cancer Research Technology Limited | SEQUENCES OF NUCLEOTIDES AND PROTEINS OF DELTA GENES OF VERTEBRATES AND METHODS BASED ON THE SAME. |
US5780300A (en) | 1995-09-29 | 1998-07-14 | Yale University | Manipulation of non-terminally differentiated cells using the notch pathway |
ATE319827T1 (en) | 1995-11-17 | 2006-03-15 | Asahi Chemical Ind | POLYPEPTIDE THAT SUPPRESSES DIFFERENTIATION |
-
1999
- 1999-05-04 US US09/310,685 patent/US6887475B1/en not_active Expired - Fee Related
-
2004
- 2004-06-25 US US10/877,563 patent/US7399741B2/en not_active Expired - Fee Related
- 2004-12-22 US US11/022,478 patent/US20060034857A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6004924A (en) * | 1991-12-11 | 1999-12-21 | Imperial Cancer Research Technology, Ltd. | Protein sequences of serrate gene products |
US7399741B2 (en) * | 1996-11-07 | 2008-07-15 | Celldex Therapeutics Limited | Notch |
US20010048930A1 (en) * | 1999-12-15 | 2001-12-06 | Lamb Jonathan Robert | Methods of immunosuppression |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080317760A1 (en) * | 2007-05-15 | 2008-12-25 | Austin Gurney | Compositions and Methods for Diagnosing and Treating Cancer |
US8802103B2 (en) | 2007-05-15 | 2014-08-12 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
US8945569B2 (en) | 2009-11-19 | 2015-02-03 | Oncomed Pharmaceuticals, Inc. | Jagged-binding agents and uses thereof |
US9416178B2 (en) | 2009-11-19 | 2016-08-16 | Oncomed Pharmaceuticals, Inc. | Jagged-binding agents and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
US7399741B2 (en) | 2008-07-15 |
US6887475B1 (en) | 2005-05-03 |
US20040241180A1 (en) | 2004-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0942998B1 (en) | Notch | |
KR100752065B1 (en) | Compositions and methods for WT1 specific immunotherapy | |
JP2002505873A (en) | Vascular endothelial growth factor 2 | |
JPH10327880A (en) | Human sodium-dependent phosphate carrier (ipt-1) | |
JP2001512667A (en) | Human orphan receptor NTR-1 | |
US20060034857A1 (en) | Notch | |
CA2621992A1 (en) | Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists | |
EP1641491B1 (en) | Increased t-cell tumor infiltration by mutant light | |
RU2197262C2 (en) | Ligands for notch | |
AU773479B2 (en) | Notch | |
JP2004041174A (en) | Pigrl-1, member of immunoglobulin gene superfamily | |
MXPA99004282A (en) | Notch | |
KR19990007806A (en) | Conversion Growth Factor α HII | |
JPH1175872A (en) | New compound | |
JP2004041175A (en) | Human lig-1 homolog (hlig-1) | |
US6746867B1 (en) | Mammalian mesoderm induction early response (MIER) gene family | |
JP2004000193A (en) | Pigr-2, member of immunoglobulin gene super-family | |
JP2001505433A (en) | Human G protein receptor HCEGH45, PACAP-like (G protein pituitary adenylate cyclase activating polypeptide-like) receptor | |
JPH11507506A (en) | Endothelial monocyte active polypeptide III | |
WO2003091390A2 (en) | Regulation of gene expression by neuromodulators and discovery of a novel ngf-induced protein termed pincher | |
JPH11514848A (en) | Melanoma-related protein | |
KR19990008320A (en) | Human neuropeptide receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CELLDEX THERAPEUTICS LIMITED,UNITED KINGDOM Free format text: CHANGE OF NAME;ASSIGNOR:LORANTIS LIMITED;REEL/FRAME:018530/0886 Effective date: 20060329 Owner name: CELLDEX THERAPEUTICS LIMITED, UNITED KINGDOM Free format text: CHANGE OF NAME;ASSIGNOR:LORANTIS LIMITED;REEL/FRAME:018530/0886 Effective date: 20060329 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |